Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : VenatoRx Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Venatorx and Melinta Update on U.S. NDA for Cefepime-Taniborbactam
Details : VNRX-5022 (cefepime) & taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor, is under development for treating complicated urinary tract infections and bacterial pneumonia in adults.
Brand Name : VNRX-5022
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2024
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : VenatoRx Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : VenatoRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims to commercialize cefepime-taniborbactam, a beta-lactam inhibitor combination antibiotic being developed for the treatment of complicated UTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adu...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : VenatoRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being used for the treatment and prevention of adult patients with candidemia and invasive candidiasis.
Brand Name : Rezzayo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 02, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Delafloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : BARDA
Deal Size : $141.9 million
Deal Type : Partnership
Details : The partnership aims to advance two antibiotics currently FDA-approved for adults, Baxdela (delafloxacin) and Vabomere (meropenem and vaborbactam), for use in pediatrics and also for the development of Baxdela against biothreat pathogens for both adults ...
Brand Name : Baxdela
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 10, 2023
Lead Product(s) : Delafloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : BARDA
Deal Size : $141.9 million
Deal Type : Partnership
Lead Product(s) : Delafloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Xediton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective produ...
Brand Name : Baxdela
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : Delafloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Xediton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rezafungin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Cidara Therapeutics
Deal Size : $460.0 million
Deal Type : Licensing Agreement
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of Rezzayo™
Details : Under the agreement, Melinta acquired exclusive rights to commercialize Rezzayo (rezafungin) in the U.S. from Cidara. Cidara recently received FDA approval for REZZAYO™, a novel, once-weekly echinocandin antifungal approved for candidemia and invasive ...
Brand Name : Rezzayo
Molecule Type : Peptide
Upfront Cash : $30.0 million
April 24, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Cidara Therapeutics
Deal Size : $460.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rezzayo (rezafungin) is a novel, once-weekly, next-generation echinocandin, an antifungal being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
Brand Name : Rezzayo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CD101 (rezafungin) is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections.
Brand Name : CD101
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 25, 2023
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Cidara Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the Agreement, Cidara will continue to lead the ongoing global Phase 3 ReSPECT prophylaxis study, as well as the regulatory activities for the approval of CD101 (rezafungin) in both the treatment and prophylaxis indications.
Brand Name : CD101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 27, 2022
Lead Product(s) : Rezafungin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Cidara Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : New American Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : TOPROL-XL®, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic, heart failure of speci...
Brand Name : Toprol-XL
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 06, 2022
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : New American Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?